These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 38751556)
21. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978 [TBL] [Abstract][Full Text] [Related]
22. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma. Bath NM; Pawlik TM Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354 [TBL] [Abstract][Full Text] [Related]
23. DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01. Jarman EJ; Horcas-Lopez M; Waddell SH; MacMaster S; Gournopanos K; Soong DYH; Musialik KI; Tsokkou P; Ng ME; Cambridge WA; Wilson DH; Kagey MH; Newman W; Pollard JW; Boulter L Liver Int; 2023 Jan; 43(1):208-220. PubMed ID: 35924447 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis. Niu S; Zhang Y; Li Z; Wang T Liver Int; 2024 Jun; ():. PubMed ID: 38829010 [TBL] [Abstract][Full Text] [Related]
25. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma. Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094 [TBL] [Abstract][Full Text] [Related]
27. FGFR2 Inhibition in Cholangiocarcinoma. Vogel A; Segatto O; Stenzinger A; Saborowski A Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665 [TBL] [Abstract][Full Text] [Related]
28. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. Lamarca A; Kapacee Z; Breeze M; Bell C; Belcher D; Staiger H; Taylor C; McNamara MG; Hubner RA; Valle JW J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899345 [TBL] [Abstract][Full Text] [Related]
29. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma. Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235 [TBL] [Abstract][Full Text] [Related]
30. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357 [TBL] [Abstract][Full Text] [Related]
31. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. Ko S; Kim M; Molina L; Sirica AE; Monga SP Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703 [TBL] [Abstract][Full Text] [Related]
32. Any role for transarterial radioembolization in unresectable intrahepatic cholangiocarcinoma in the era of advanced systemic therapies? Elvevi A; Laffusa A; Elisei F; Morzenti S; Guerra L; Rovere A; Invernizzi P; Massironi S World J Hepatol; 2023 Dec; 15(12):1284-1293. PubMed ID: 38223418 [TBL] [Abstract][Full Text] [Related]
33. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Bekaii-Saab TS; Bridgewater J; Normanno N Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504 [TBL] [Abstract][Full Text] [Related]